A field-deployable gamma-ray spectrometer utilizing high pressure xenon

Most nuclear materials in the nuclear energy, safeguards, arms control, and nonproliferation regimes emit gamma rays with a unique signature. Currently, two categories of spectrometers are available to evaluate these materials: (1) Semiconductors, with excellent energy resolution, which operate at cryogenic temperatures. (2) Scintillation detectors, which function at ambient temperature, but with poor energy resolution. A detector which functions for extended periods in a range of environments, with an energy resolution superior to that of a scintillation spectrometer, would have evident utility. Recently, in the research community, such a device has evolved, an ionization chamber utilizing xenon gas at very high pressure (60 atm). Its energy resolution, typically, is 20 keV for the 661 keV gamma ray of {sup 137}Cs. With high xenon density and its high atomic number (Z=54), and superior energy resolution, its sensitivity is comparable to that of a scintillator

A portable gamma-ray spectrometer using compressed xenon

An ionization chamber using compressed xenon has been designed and built for gamma-ray spectrometry. The device is based on signal measurement from a parallel plate detector, with the gas enclosure constructed specifically for packaging into a portable instrument; thus, appropriate engineering practices comprises two small containers that can be setup for operation in just a few minutes. Its sensitivity is 100 keV to over 1 MeV, with a resolution at 662 keV of 2.5% FWHM for uniform irradiation, and 2% FWHM for collimated irradiation, comparable to the best ever with compressed xenon. It also exhibits greater specificity that most scintillators, such as NaI. The device is insensitive to neutron damage and has a low power requirement

Long-Baseline Neutrino Facility (LBNF) and Deep Underground Neutrino Experiment (DUNE) Conceptual Design Report Volume 2: The Physics Program for DUNE at LBNF

The Physics Program for the Deep Underground Neutrino Experiment (DUNE) at the Fermilab Long-Baseline Neutrino Facility (LBNF) is described

A protective role for T lymphocytes in asbestos-induced pulmonary inflammation and collagen deposition

Several lines of evidence have suggested that specific (i.e., lymphocyte) immunity plays a role in chemical-induced pulmonary diseases, including asbestosis. To evaluate the influence of cell-mediated immunity in pulmonary inflammation and fibrosis evoked by asbestos fibers, we compared the effects of asbestos in immunodeficient mice (Balb/c nu/nu and severe combined immunodeficient [C3H-SCID]), immunologically normal mice of the same genetic background, and immunodeficient mice reconstituted with syngeneic T lymphocytes. Increases in lavaged cell numbers occurred in asbestos-treated immunodeficient mice compared with asbestos-treated immunocompetent or immunodeficient mice that received T lymphocytes. Differential analysis of the collected cells in treated mice demonstrated a predominantly neutrophilic infiltrate that correlated with increased levels of leukotriene B4 and prostaglandin E2. There were no significant differences between immunocompetent and athymic asbestos-treated mice in bronchoalveolar lavaged total protein. However, asbestos-treated SCID mice revealed a significant increase in protein content and lactate dehydrogenase activity compared with asbestos-treated normal mice, which did not occur in T lymphocyte-reconstituted SCID mice. Fibronectin levels were elevated in asbestos-exposed athymic mice when compared with air-exposed athymic mice or asbestos-exposed immunocompetent mice. Both asbestos-treated athymic and SCID mice showed a significant increase in total lung hydroxyproline when compared with asbestos-treated immunocompetent mice. Lung hydroxyproline was also reduced in asbestos-exposed SCID mice after T lymphocyte reconstitution and, conversely, increased in T cell-depleted Balb/c mice.(ABSTRACT TRUNCATED AT 250 WORDS

A field-deployable gamma-ray spectrometer utilizing xenon at high pressure

Prototype gamma-ray spectrometers utilizing xenon gas at high pressure, suitable for applications in the nuclear safeguards, arms control, and nonproliferation communities, have been developed at Brookhaven National Laboratory (BNL). These spectrometers function as ambient-temperature ionization chambers detecting gamma rays with good efficiency in the energy range 50 keV - 2 MeV, with an energy resolution intermediate between semiconductor (Ge) and scintillation (NaI) spectrometers. They are capable of prolonged, low-power operation without a requirement for cryogenic fluids or other cooling mechanisms, and with the addition of small quantities of {sup 3}He gas, can function simultaneously as efficient thermal neutron detectors

Clinical endpoints in peripheral endovascular revascularization trials: a case for standardized definitions

BACKGROUND: Endovascular therapy is a rapidly expanding option for the treatment of patients with peripheral arterial disease (PAD), leading to a myriad of published studies reporting on various revascularization strategies. However, these reports are often difficult to interpret and compare because they do not utilize uniform clinical endpoint definitions. Moreover, few of these studies describe clinical outcomes from a patients' perspective. METHODS AND RESULTS: The DEFINE Group is a collaborative effort of an ad-hoc multidisciplinary team from various specialties involved in peripheral arterial disease therapy in Europe and the United States. DEFINE's goal was to arrive at a broad based consensus for baseline and endpoint definitions in peripheral endovascular revascularization trials for chronic lower limb ischemia. In this project, which started in 2006, the individual team members reviewed the existing pertinent literature. Following this, a series of telephone conferences and face-to-face meetings were held to agree upon definitions. Input was also obtained from regulatory (United States Food and Drug Administration) and industry (device manufacturers with an interest in peripheral endovascular revascularization) stakeholders, respectively. The efforts resulted in the current document containing proposed baseline and endpoint definitions in chronic lower limb PAD. Although the consensus has inevitably included certain arbitrary choices and compromises, adherence to these proposed standard definitions would provide consistency across future trials, thereby facilitating evaluation of clinical effectiveness and safety of various endovascular revascularization techniques. CONCLUSION: This current document is based on a broad based consensus involving relevant stakeholders from the medical community, industry and regulatory bodies. It is proposed that the consensus document may have value for study design of future clinical trials in chronic lower limb ischemia as well as for regulatory purposes